Joanne Xiu

TL;DR: The rarity of NTRK genes fusions outside the brain malignancies is confirmed and strategies for detection of the N TRK fusion-driven cancers may include immunohistochemistry, but gene fusion detection remains the most reliable tool.

TL;DR: On the basis of a variety of potential biomarkers of response to immune checkpoints, only small subsets of glioma patients are likely to benefit from monotherapy immune checkpoint inhibition.

TL;DR: HR-DDR mutations were seen in 17.4% of tumors across 21 cancer lineages, providing a path to explore the role of HRD-directed therapies, including poly-ADP ribose polymerase inhibitors, DNA-damaging chemotherapies, and newer agents such as ATR inhibitors.

TL;DR: Although MSI is conceivably the main driver for TML-high, other factors may be involved and future clinical trials are needed to evaluate whether the integration of TML, MSI, and PD-L1 could better identify potential responders to immunotherapy.

TL;DR: The site of tumor origin (left colon, right colon, or rectum) should certainly be considered when selecting treatment regimens and stratifying patients for future clinical trials, and molecular variations among right-sided colon, left-sided Colon, and rectal tumors may contribute to differences in clinical behavior.